A risky but often lifesaving surgery that removes damaged parts of the small intestine can leave patients facing a new threat: serious liver damage with no available treatment. Now, scientists have ...
Compliance & Enforcement Team explores the U.S. Food and Drug Administration’s new draft guidance on responding to FDA Form 483 ...
Morning Overview on MSN
Engineered bacteria deliver chemo drug inside tumors in mice
Researchers at the National University of Singapore have engineered a common gut bacterium to carry a chemotherapy prodrug ...
Having recently announced a new Systemic Anti-Cancer Therapy (SACT) centre in Royal Tunbridge Wells, today GenesisCare confirms they will expand their UK network yet again with an additional SACT ...
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Bre ...
Discover how therapeutic peptides act as biological messengers to treat disease, improve metabolism, and enhance immune ...
Clinical and payer strategies should treat GLP‑1 therapy as chronic for high-risk patients, addressing tolerability and cost ...
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
What does the exit of Vladimir Padrino López mean for criminal dynamics in Venezuela and the future of the Cartel of the Suns ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results